SEMNUR PHARMACEUTICALS, INC.
SMNR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SMNR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SMNR
SEMNUR PHARMACEUTICALS, INC. (SMNR) is a late-stage clinical specialty pharmaceutical company focused on developing non-opioid therapeutics for pain management, with its sole product candidate SP-102 (corticosteroid lumbar epidural injection) currently in Phase 3 trials.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for SEMNUR PHARMACEUTICALS, INC..
SEMNUR PHARMACEUTICALS, INC. (SMNR) is a late-stage clinical specialty pharmaceutical company focused on developing non-opioid therapeutics for pain management, with its sole product candidate SP-102 (corticosteroid lumbar epidural injection) currently in Phase 3 trials.
- Semnur Pharmaceuticals has only one product candidate, SP-102, and no products approved for commercial sale, having never generated any revenue from product sales [sec · filed 2025-10-21].
- As of June 30, 2026, the company had cash and cash equivalents of $0.0M, a net loss of $4.3M, negative shareholders' equity of $44.4M, and total debt of $2.1M [sec].
- The company's financial statements include a going concern qualification, indicating substantial doubt about its ability to continue as a going concern for at least one year [sec_mda · as of 2026-08-10].
- Semnur is dependent on the clinical success and regulatory approval of SP-102, and faces risks common to late-stage pharmaceutical companies including the need for substantial additional financing [sec_mda · as of 2026-08-10].
- The company plans to expand its product portfolio by developing or acquiring non-opioid assets that leverage its existing research and development infrastructure [sec_mda · as of 2026-02-27].
What works
- Semnur is a late-stage clinical company with a sole product candidate, SP-102, which is in Phase 3 trials for radicular pain, indicating a focused development strategy [sec_mda · as of 2026-08-10].
- The company aims to address an unmet need in pain management by developing non-opioid therapeutics that could reduce reliance on opioids and invasive procedures like spinal surgery [sec_mda · as of 2026-02-27].
- Semnur is actively evaluating opportunities to expand its pipeline through selective acquisitions of highly differentiated technologies and early/late-stage research programs [sec_mda · as of 2026-02-27].
What to weigh
- Semnur has no approved products, no revenue from product sales, and an accumulated deficit of approximately $116.0 million as of June 30, 2025, highlighting a lack of commercial validation [sec · filed 2025-10-21].
- The company's cash position of $0.0M as of June 30, 2026, and negative shareholders' equity of $44.4M indicate severe liquidity constraints and reliance on external financing [sec].
- The company's financial statements include a going concern qualification, reflecting substantial doubt about its ability to continue operations without additional funding [sec_mda · as of 2026-08-10].
- Semnur faces significant competition, untested manufacturing capabilities, and dependency on the clinical and regulatory success of SP-102, with no guarantee of approval [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
The company has only one product candidate, SP-102, and no approved products.
“We have only one product candidate, SP-102, no products approved for commercial sale, have never generated any revenue from product sales and may never be profitable.”
SEC filings · October 21, 2025
The company's financial statements include a going concern qualification.
“The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.”
SEC MD&A · August 10, 2026
The company has an accumulated deficit of approximately $116.0 million.
“As of June 30, 2025, our cash and cash equivalents were approximately $55,000 and we had an accumulated deficit of approximately $116.0 million.”
SEC filings · October 21, 2025
The company plans to expand its product portfolio by developing or acquiring non-opioid assets.
“Expand our product portfolio by developing or acquiring non-opioid assets that leverage our existing research and development infrastructure.”
SEC MD&A · February 27, 2026
Catalyst timeline
- 2029-01-01 · Phase3_Topline · sp-102 — Phase 3 Topline: Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-bli — Topline results from the Phase 3 C.L.E.A.R 2 trial for SP-102 are expected, which will be a key determinant of the product candidate's regulatory path.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's financial statements include a going concern qualification, indicating substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-10].
- Dependence on SP-102 — Semnur has only one product candidate, SP-102, and its future depends on the clinical success and regulatory approval of this candidate [sec_mda · as of 2026-08-10].
- Need for additional financing — The company requires substantial additional financing to fund its operations and development activities, with no guarantee of securing such funding [sec_mda · as of 2026-08-10].
- No revenue or profitability — The company has never generated any revenue from product sales and may never become profitable [sec · filed 2025-10-21].
What to watch
- Phase 3 topline data for SP-102 (C.L.E.A.R 2 trial) expected around 2029-01-01 [upcoming catalysts].
- Ability to secure additional financing to fund ongoing operations and clinical development [sec_mda · as of 2026-08-10].
- Regulatory interactions and potential approval decisions for SP-102 [sec_mda · as of 2026-08-10].
- Progress in expanding the product portfolio through acquisitions or in-licensing of non-opioid assets [sec_mda · as of 2026-02-27].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run SEMNUR PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SEMNUR PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.5 months
OCF -$2M · Net income -$4M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~855d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for SEMNUR PHARMACEUTICALS, INC.?
SEMNUR PHARMACEUTICALS, INC. (SMNR) is a late-stage clinical specialty pharmaceutical company focused on developing non-opioid therapeutics for pain management, with its sole product candidate SP-102 (corticosteroid lumbar epidural injection) currently in Phase 3 trials.
What is SEMNUR PHARMACEUTICALS, INC.'s next catalyst?
SEMNUR PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-bli" — expected January 1, 2029.
Who is the CEO of SEMNUR PHARMACEUTICALS, INC.?
Dr. Henry H. Ji Ph.D. is the chief executive officer of SEMNUR PHARMACEUTICALS, INC. (SMNR).
Where is SEMNUR PHARMACEUTICALS, INC. headquartered?
SEMNUR PHARMACEUTICALS, INC. (SMNR) is headquartered in Palo Alto, CA, United States.
What therapeutic areas does SEMNUR PHARMACEUTICALS, INC. focus on?
SEMNUR PHARMACEUTICALS, INC. develops therapies across Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.